Literature DB >> 33618742

Surfactant therapies for pediatric and neonatal ARDS: ESPNIC expert consensus opinion for future research steps.

Daniele De Luca1,2, Paola Cogo3, Martin C Kneyber4,5, Paolo Biban6, Malcolm Grace Semple7, Jesus Perez-Gil8, Giorgio Conti9, Pierre Tissieres10,11, Peter C Rimensberger12.   

Abstract

Pediatric (PARDS) and neonatal (NARDS) acute respiratory distress syndrome have different age-specific characteristics and definitions. Trials on surfactant for ARDS in children and neonates have been performed well before the PARDS and NARDS definitions and yielded conflicting results. This is mainly due to heterogeneity in study design reflecting historic lack of pathobiology knowledge. We reviewed the available clinical and preclinical data to create an expert consensus aiming to inform future research steps and advance the knowledge in this area. Eight trials investigated the use of surfactant for ARDS in children and ten in neonates, respectively. There were improvements in oxygenation (7/8 trials in children, 7/10 in neonates) and mortality (3/8 trials in children, 1/10 in neonates) improved. Trials were heterogeneous for patients' characteristics, surfactant type and administration strategy. Key pathobiological concepts were missed in study design. Consensus with strong agreement was reached on four statements: 1. There are sufficient preclinical and clinical data to support targeted research on surfactant therapies for PARDS and NARDS. Studies should be performed according to the currently available definitions and considering recent pathobiology knowledge. 2. PARDS and NARDS should be considered as syndromes and should be pre-clinically studied according to key characteristics, such as direct or indirect (primary or secondary) nature, clinical severity, infectious or non-infectious origin or patients' age. 3. Explanatory should be preferred over pragmatic design for future trials on PARDS and NARDS. 4. Different clinical outcomes need to be chosen for PARDS and NARDS, according to the trial phase and design, trigger type, severity class and/or surfactant treatment policy. We advocate for further well-designed preclinical and clinical studies to investigate the use of surfactant for PARDS and NARDS following these principles.

Entities:  

Keywords:  Children; Infant; NARDS; Neonate; PARDS; Surfactant

Year:  2021        PMID: 33618742      PMCID: PMC7898495          DOI: 10.1186/s13054-021-03489-6

Source DB:  PubMed          Journal:  Crit Care        ISSN: 1364-8535            Impact factor:   9.097


  75 in total

1.  A role for phospholipase A2 in ARDS pathogenesis.

Authors:  L Touqui; L Arbibe
Journal:  Mol Med Today       Date:  1999-06

2.  Personalising care of acute respiratory distress syndrome according to patients' age.

Authors:  Daniele De Luca
Journal:  Lancet Respir Med       Date:  2018-10-22       Impact factor: 30.700

3.  Pediatric acute respiratory distress syndrome: definition, incidence, and epidemiology: proceedings from the Pediatric Acute Lung Injury Consensus Conference.

Authors:  Robinder G Khemani; Lincoln S Smith; Jerry J Zimmerman; Simon Erickson
Journal:  Pediatr Crit Care Med       Date:  2015-06       Impact factor: 3.624

Review 4.  Diverse macrophage populations mediate acute lung inflammation and resolution.

Authors:  Neil R Aggarwal; Landon S King; Franco R D'Alessio
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-02-07       Impact factor: 5.464

Review 5.  Surfactant therapy for acute lung injury and acute respiratory distress syndrome.

Authors:  Krishnan Raghavendran; D Willson; R H Notter
Journal:  Crit Care Clin       Date:  2011-07       Impact factor: 3.598

Review 6.  The pulmonary endothelium in acute respiratory distress syndrome: insights and therapeutic opportunities.

Authors:  Fraser R Millar; Charlotte Summers; Mark J Griffiths; Mark R Toshner; Alastair G Proudfoot
Journal:  Thorax       Date:  2016-03-11       Impact factor: 9.139

7.  The Montreux definition of neonatal ARDS: biological and clinical background behind the description of a new entity.

Authors:  Daniele De Luca; Anton H van Kaam; David G Tingay; Sherry E Courtney; Olivier Danhaive; Virgilio P Carnielli; Luc J Zimmermann; Martin C J Kneyber; Pierre Tissieres; Joe Brierley; Giorgio Conti; Jane J Pillow; Peter C Rimensberger
Journal:  Lancet Respir Med       Date:  2017-07-04       Impact factor: 30.700

8.  Ventilator-induced lung injury. Similarity and differences between children and adults.

Authors:  Martin C J Kneyber; Haibo Zhang; Arthur S Slutsky
Journal:  Am J Respir Crit Care Med       Date:  2014-08-01       Impact factor: 21.405

Review 9.  Surfactant alteration and replacement in acute respiratory distress syndrome.

Authors:  A Günther; C Ruppert; R Schmidt; P Markart; F Grimminger; D Walmrath; W Seeger
Journal:  Respir Res       Date:  2001-10-12

10.  Clinical and biological role of secretory phospholipase A2 in acute respiratory distress syndrome infants.

Authors:  Daniele De Luca; Elena Lopez-Rodriguez; Angelo Minucci; Francesca Vendittelli; Leonarda Gentile; Eleonora Stival; Giorgio Conti; Marco Piastra; Massimo Antonelli; Mercedes Echaide; Jesus Perez-Gil; Ettore D Capoluongo
Journal:  Crit Care       Date:  2013-07-24       Impact factor: 9.097

View more
  6 in total

1.  Reduced DMPC and PMPC in lung surfactant promote SARS-CoV-2 infection in obesity.

Authors:  Kang Du; Ling Sun; Zichen Luo; Yang Cao; Qiushi Sun; Kangzhen Zhang; Ahmed Faizy; Daniele Piomelli; Xiang Lu; Jinjun Shan; Qin Yang
Journal:  Metabolism       Date:  2022-03-18       Impact factor: 13.934

2.  Rare-variant collapsing analyses identified risk genes for neonatal acute respiratory distress syndrome.

Authors:  Huiyao Chen; Xiang Chen; Liyuan Hu; Chang Ye; Jiantao Zhang; Guoqiang Cheng; Lin Yang; Yulan Lu; Xinran Dong; Wenhao Zhou
Journal:  Comput Struct Biotechnol J       Date:  2022-09-01       Impact factor: 6.155

3.  Exogenous pulmonary surfactant in COVID-19 ARDS. The similarities to neonatal RDS suggest a new scenario for an 'old' strategy.

Authors:  Reena M Bhatt; Howard W Clark; Massimo Girardis; Stefano Busani
Journal:  BMJ Open Respir Res       Date:  2021-09

4.  The International Week of Surfactant Research: Increasing knowledge about surfactant and unexploited opportunities.

Authors:  Daniele De Luca; Lhoussaine Touqui
Journal:  Biomed J       Date:  2021-07-24       Impact factor: 4.910

Review 5.  Strategies to protect surfactant and enhance its activity.

Authors:  Daniele De Luca; Chiara Autilio
Journal:  Biomed J       Date:  2021-08-05       Impact factor: 4.910

Review 6.  A recipe for a good clinical pulmonary surfactant.

Authors:  Jesús Pérez-Gil
Journal:  Biomed J       Date:  2022-03-08       Impact factor: 7.892

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.